DESTINY-Breast03 trial: some questions remain – Authors’ reply

By sjmartinez • May 21, 2023

Hurvitz SA, Curigliano G, Egorov A, Ashfaque S, Cortés J. DESTINY-Breast03 trial: some questions remain - Authors' reply. Lancet. 2023 May 20;401(10389):1653-1654. doi: 10.1016/S0140-6736(23)00681-5. PMID: 37210117.

Tags: Hematology/Oncology, Publications

Related Posts

Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial

Soto-Perez-de-Celis E, Dale W, Katheria V, Kim H, Fakih M, Chung VM, Lim D, Mortimer J, Cabrera Chien L, Charles K, Roberts E, Vazquez J,[...]

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024

Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Cortese M, Cripe L, Davis RS, Eradat H, Fakhri B, Fletcher[...]

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan[...]